Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
종목 코드 GH
회사 이름Guardant Health Inc
상장일Oct 04, 2018
설립일2011
CEODr. Amirali Talasaz, Ph.D.
직원 수1999
유형Ordinary Share
회계 연도 종료Oct 04
주소3100 Hanover Street
도시PALO ALTO
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호94304
전화18556988887
웹사이트https://guardanthealth.com/
종목 코드 GH
상장일Oct 04, 2018
설립일2011
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음